摘要
目的:探讨eRF3a/GSPT1和CyclinD1在甲状腺乳头状癌(papillary thyroid carcinoma, PTC)及周边正常甲状腺组织中的表达,分析eRF3a/GSPT1和CyclinD1表达在PTC中的相关性及临床病理意义。方法:采用免疫组化检测eRF3a/GSPT1和CyclinD1在80例PTC及72例周边正常甲状腺组织中的表达情况,分析eRF3a/GSPT1和CyclinD1表达水平与PTC临床病理特征的关系及两者表达的相关性。结果:eRF3a/GSPT1和CyclinD1在PTC组织中的表达明显高于周边正常甲状腺组织;eRF3a/GSPT1的表达差异在肿瘤大小、甲状腺被膜侵犯中具有统计学意义;CyclinD1的表达差异在多灶发生、淋巴结转移中具有统计学意义;在PTC中eRF3a/GSPT1与CyclinD1的表达呈现正相关。结论:eRF3a/GSPT1和CyclinD1在PTC组织中高表达,可能成为PTC潜在的诊断标志物;eRF3a/GSPT1的表达与肿瘤大小和甲状腺被膜侵犯有关,可能促进PTC的发生、发展,CyclinD1对PTC淋巴结转移有提示作用;eRF3a/GSPT1和CyclinD1可能协同促进PTC的发生、发展。
Objective:To investigate the expression of eRF3 a/GSPT1 and CyclinD1 in papillary thyroid carcinoma(PTC)and peripheral normal thyroid tissues, and to analyze the correlation and clinicopathological significance of the expression of eRF3 a/GSPT1 and CyclinD1 in PTC.Methods:The expression of eRF3 a/GSPT1 and CyclinD1 in 80 cases of PTC and 72 cases of peripheral normal thyroid tissue was detected by immunohistochemistry.To analyze the relationship between the expression levels of eRF3 a/GSPT1 and CyclinD1 and the clinicopathological features of PTC and their correlation.Results:The expression of eRF3 a/GSPT1 and CyclinD1 in PTC was significantly higher than that in peripheral normal thyroid tissue.The expression difference of eRF3 a/GSPT1 was statistically significant in tumor size and thyroid capsule invasion.The expression difference of CyclinD1 was statistically significant in multifocal and lymph node metastasis.The expression of eRF3 a/GSPT1 was positively correlated with CyclinD1 in PTC.Conclusion:eRF3 a/GSPT1 and CyclinD1 is highly expressed in PTC tissues, which may be a potential diagnostic marker of PTC.The expression of eRF3 a/GSPT1 is related to tumor size and thyroid capsule invasion, and may promote the occurrence and development of PTC.CyclinD1 has a suggestive effect on PTC lymph node metastasis.ERF3 a/GSPT1 and CyclinD1 may synergistically promote the occurrence and development of PTC.
作者
吴丽萍
丁洋
王大维
王晓萌
陈剑英
肖雪兰
高峰
WU Liping;DING Yang;WANG Dawei;WANG Xiaomeng;CHEN Jianying;XIAO Xuelan;GAO Feng(Department of Pathology,the Third Hospital of Hebei Medical University,Hebei Shijiazhuang 050051,China;Department of Oral Surgery,the Third Hospital of Hebei Medical University,Hebei Shijiazhuang 050051,China)
出处
《现代肿瘤医学》
CAS
北大核心
2022年第20期3688-3692,共5页
Journal of Modern Oncology